pharmaphorum January 17, 2022
The adoption of decentralised activities was a major factor in allowing clinical trials to continue during the early stages of the pandemic. Ben Hargreaves examines whether this adoption looks set to become a permanent feature of clinical trials moving into the future, rather than just supplying the tools to a temporary need.
Decentralised clinical trials (DCTs) have become a major talking point due to their ability to ensure that drug development can continue efficiently through the current pandemic. The arrival of COVID-19 meant that certain virtual technologies became essential for clinical trials to continue, bringing certain activities into the patient’s home and allowing for further activities to be conducted remotely.
This transition was already underway; however, with clinical trial activity...
Today's Sponsors
Today's Sponsor